Cetera Trust Company N.A Invests $142,000 in CareDx, Inc (NASDAQ:CDNA)

Cetera Trust Company N.A bought a new stake in shares of CareDx, Inc (NASDAQ:CDNA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,870 shares of the company’s stock, valued at approximately $142,000.

Other large investors also recently added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new stake in CareDx during the third quarter valued at approximately $72,000. Nisa Investment Advisors LLC grew its position in CareDx by 442.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,440 shares of the company’s stock valued at $77,000 after buying an additional 5,253 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in CareDx by 23.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,751 shares of the company’s stock valued at $82,000 after buying an additional 2,211 shares during the period. Sherbrooke Park Advisers LLC bought a new stake in CareDx during the third quarter valued at approximately $85,000. Finally, Principal Financial Group Inc. grew its position in CareDx by 14.3% during the third quarter. Principal Financial Group Inc. now owns 17,635 shares of the company’s stock valued at $123,000 after buying an additional 2,205 shares during the period.

CareDx Price Performance

Shares of NASDAQ:CDNA opened at $8.17 on Tuesday. CareDx, Inc has a 1-year low of $4.80 and a 1-year high of $12.93. The company has a market capitalization of $423.04 million, a P/E ratio of -2.31 and a beta of 1.42. The firm’s 50 day simple moving average is $9.64 and its two-hundred day simple moving average is $9.21.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($1.97). CareDx had a negative net margin of 67.88% and a negative return on equity of 51.40%. The firm had revenue of $65.57 million for the quarter, compared to analysts’ expectations of $63.66 million. During the same period in the prior year, the firm earned ($0.34) EPS. CareDx’s revenue for the quarter was down 20.4% compared to the same quarter last year. On average, sell-side analysts anticipate that CareDx, Inc will post -1.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Stephens restated an “overweight” rating and set a $15.00 target price on shares of CareDx in a research report on Wednesday, April 17th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $13.50.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.